Drug Profile
CDX 1402
Alternative Names: CDX1402Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Celldex Therapeutics Inc
- Class Antineoplastics; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; DEC-205 receptor agonists; Dendritic cell stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 05 Apr 2017 Preclinical trials in Cancer in USA prior to April 2017 (unspecified route)
- 05 Apr 2017 Results from a preclinical trial in Cancer reported at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)